	US 12,139,485 B2
	Azabenzimidazoles and their use as AMPA receptor modulators
Michael K. Ameriks, San Diego, CA (US); Gang Chen, San Diego, CA (US); Bradley M. Savall, San Diego, CA (US); Devin M. Swanson, Carlsbad, CA (US); Wei Zhang, San Diego, CA (US); and Dongpei Wu, San Diego, CA (US)
Assigned to Janssen Pharmaceutica NV, Beerse (BE)
Filed by Janssen Pharmaceutica NV, Beerse (BE)
Filed on Oct. 17, 2022, as Appl. No. 17/967,483.
Application 17/967,483 is a continuation of application No. 17/324,520, filed on May 19, 2021.
Application 17/324,520 is a continuation of application No. 15/569,299, granted, now 11,312,712, issued on Apr. 26, 2022, previously published as PCT/US2016/029801, filed on Apr. 28, 2016.
Claims priority of provisional application 62/154,313, filed on Apr. 29, 2015.
Prior Publication US 2023/0110576 A1, Apr. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61P 25/00 (2006.01); C07D 471/14 (2006.01)

CPC C07D 471/04 (2013.01) [A61P 25/00 (2018.01); C07D 471/14 (2013.01); C07C 2601/02 (2017.05); C07C 2601/04 (2017.05); C07C 2601/08 (2017.05); C07C 2601/14 (2017.05); C07C 2601/16 (2017.05)]

4 Claims

1. A method of conducting an imaging study, comprising administering to a subject in need thereof a composition comprising 2-(2-[18F]fluoro-4-pyridyl)-3-(7-methyl-1H-indazol-5-yl)-5-(trifluoromethyl)imidazo[4,5-b]pyridine, or a pharmaceutically acceptable salt, N-oxide, or solvate thereof.